APLS Share Price Performance
US$18.87
-6.24 (-24.85%)
44.4% undervalued intrinsic discount
US$33.95
Fair Value
Price US$18.87
AnalystConsensusTarget US$33.95
AnalystHighTarget US$55.00
AnalystLowTarget US$19.00
Fair ValueUS$33.95
Share Pricen/a
Apellis Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 22 Fair Values set on narratives written by author
APLS Community Narratives
AN
Fair Value US$33.95 44.4% undervalued intrinsic discount
APLS: Uptake In Rare Kidney Disease Segment Will Drive Future Upside
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value US$55 65.7% undervalued intrinsic discount
Expanded Labels And Complement Pipeline Will Capture Global Aging Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$19 0.7% undervalued intrinsic discount
Rising FDA And Payer Pressures Will Limit Market Traction
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Expanded Labels And Complement Pipeline Will Capture Global Aging Markets
Key Takeaways EMPAVELI and SYFOVRE are positioned to capture dominant market shares and drive sustained revenue growth through broad adoption and durable clinical efficacy. Advances in pipeline therapies and operational discipline strengthen both profit margins and long-term earnings leverage, setting Apellis apart from industry peers.Read more
15
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$55
65.7% undervalued intrinsic discount
Fair Value
Revenue
14.05% p.a.
Profit Margin
28.13%
Future PE
21.78x
Price in 2029
US$67.84
APLS: Uptake In Rare Kidney Disease Segment Will Drive Future Upside
Key Takeaways Expansion into rare kidney diseases and strong leadership in eye disease treatments set the stage for revenue growth and increased market reach. Enhanced balance sheet and operational efficiency enable greater investment in R&D and commercialization, supporting profitability and long-term earnings potential.Read more
211
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
US$33.95
44.4% undervalued intrinsic discount
Fair Value
Revenue
4.59% p.a.
Profit Margin
4.78%
Future PE
97.34x
Price in 2029
US$41.92
Rising FDA And Payer Pressures Will Limit Market Traction
Key Takeaways Heavy reliance on two core products and high R&D costs leave Apellis vulnerable to shifting market forces and uncertain pipeline outcomes. Growing regulatory challenges, reimbursement limits, and rising competition threaten revenue growth, market share, and the company's long-term profitability prospects.Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$19
0.7% undervalued intrinsic discount
Fair Value
Profit Margin
16.25%
Future PE
18.68x
Price in 2028
US$23.15
Trending Discussion
Recently Updated Narratives
AN
APLS: Future C3G Launch Execution Will Drive Bullish Re Rating Potential
Fair Value: US$55 65.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
APLS: Kidney Disease Launch And Index Adds Will Support Future Repricing
Fair Value: US$33.95 44.4% undervalued intrinsic discount
12 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising FDA And Payer Pressures Will Limit Market Traction
Fair Value: US$19 0.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Apellis Pharmaceuticals, Inc. Key Details
About APLS
- Founded
- 2009
- Employees
- 736
- CEO
- WebsiteView website
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.
